Profound Medical Corp. The company is headquartered in Mississauga, Canada.
| Revenue (TTM) | $19.09M |
| Gross Profit (TTM) | $13.70M |
| EBITDA | $-34.88M |
| Operating Margin | -445.70% |
| Return on Equity | -73.50% |
| Return on Assets | -39.50% |
| Revenue/Share (TTM) | $0.57 |
| Book Value | $1.83 |
| Price-to-Book | 5.03 |
| Price-to-Sales (TTM) | 13.80 |
| EV/Revenue | 11.59 |
| EV/EBITDA | -5.75 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 12.30% |
| Shares Outstanding | $36.54M |
| Float | $35.50M |
| % Insiders | 4.09% |
| % Institutions | 45.41% |
Volatility is currently contracting
Profound Medical NASDAQ: PROF reported an 86% increase in third-quarter revenue and raised its full-year revenue outlook, as sales of its TULSA-PRO equipment helped drive growth ahead of a planned leadership transition.
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach
TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that Emmy Award-winning television host, health advocate and decorated U.S. Navy veteran, Montel Williams, will join the next Let's Huddle webinar for a discussion with its host, Leonard Wheeler, on November 5, 2026, at 3:00 p.m. ET. Mr. Williams will share his personal perspectives on health advocacy, resilience, informed healthcare decisions and the importance of protecting quality of life.
The mean of analysts' price targets for Profound Medical (PROF) points to a 58.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO ® system.
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce entering into a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) (“Telix”), a commercial-stage global radiopharmaceutical company. The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's advanced prostate-specific membrane antigen (“PSMA”) targeting PET molecular imaging technologies, Gozellix® and Illuccix® 1, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO® platform across the prostate care continuum.
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47%
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PROF and any ticker you trade — then tracks every position and per-strategy win rate.
